| Item Type | Name |
|
Concept
|
Breast Neoplasms
|
|
Academic Article
|
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
|
|
Academic Article
|
The molecular portraits of breast tumors are conserved across microarray platforms.
|
|
Academic Article
|
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
|
|
Academic Article
|
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
|
|
Academic Article
|
Advances in breast cancer: pathways to personalized medicine.
|
|
Academic Article
|
Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.
|
|
Academic Article
|
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.
|
|
Academic Article
|
"Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
|
|
Academic Article
|
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
|
|
Academic Article
|
Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions.
|
|
Academic Article
|
Phase II trial of temsirolimus in patients with metastatic breast cancer.
|
|
Academic Article
|
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
|
|
Academic Article
|
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.
|
|
Academic Article
|
The role of tumor-associated macrophages in breast cancer progression (review).
|
|
Academic Article
|
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
|
|
Academic Article
|
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.
|
|
Academic Article
|
Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment.
|
|
Academic Article
|
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
|
|
Academic Article
|
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.
|
|
Academic Article
|
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
|
|
Academic Article
|
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
|
|
Academic Article
|
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).
|
|
Academic Article
|
Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017.
|
|
Academic Article
|
A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer.
|
|
Academic Article
|
Adaptive Randomization of Neratinib in Early Breast Cancer.
|
|
Academic Article
|
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
|
|
Academic Article
|
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
|
|
Academic Article
|
Concepts and targets in triple-negative breast cancer: recent results and clinical implications.
|
|
Academic Article
|
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
|
|
Academic Article
|
Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients.
|
|
Academic Article
|
Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
|
|
Academic Article
|
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.
|
|
Academic Article
|
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
|
|
Academic Article
|
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
|
|
Academic Article
|
Immune Checkpoint Blockade for Breast Cancer.
|
|
Academic Article
|
Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers.
|
|
Academic Article
|
Immune Checkpoint Inhibitor Therapy in Breast Cancer.
|
|
Academic Article
|
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
|
|
Academic Article
|
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
|
|
Academic Article
|
First international TNBC conference meeting report.
|
|
Academic Article
|
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
|
|
Academic Article
|
Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
|
|
Academic Article
|
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.
|
|
Academic Article
|
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
|
|
Academic Article
|
If we build it they will come: targeting the immune response to breast cancer.
|
|
Academic Article
|
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer.
|
|
Academic Article
|
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
|
|
Academic Article
|
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
|
|
Academic Article
|
Atezolizumab for the treatment of breast cancer.
|
|
Academic Article
|
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
|
|
Academic Article
|
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
|
|
Academic Article
|
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
|
|
Academic Article
|
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
|
|
Academic Article
|
Racial disparities in survival outcomes among breast cancer patients by molecular subtypes.
|
|
Academic Article
|
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
|
|
Academic Article
|
Novel therapies for triple-negative breast cancer.
|
|
Academic Article
|
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
|
|
Academic Article
|
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
|
|
Academic Article
|
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
|
|
Academic Article
|
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
|
|
Academic Article
|
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
|
|
Academic Article
|
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
|
|
Academic Article
|
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
|
|
Academic Article
|
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer.
|
|
Academic Article
|
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
|
|
Academic Article
|
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
|
|
Academic Article
|
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
|
|
Academic Article
|
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.
|
|
Academic Article
|
Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy.
|
|
Academic Article
|
Clinical trials of immunotherapy in triple-negative breast cancer.
|
|
Academic Article
|
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform.
|
|
Academic Article
|
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.
|
|
Academic Article
|
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.
|
|
Academic Article
|
The evolving therapeutic landscape of antibody-drug conjugates in breast cancer.
|
|
Academic Article
|
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.
|
|
Academic Article
|
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
|
|
Academic Article
|
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.
|
|
Concept
|
Triple Negative Breast Neoplasms
|
|
Academic Article
|
The Impact of Race and Age on Response to Neoadjuvant Therapy and Long-Term Outcomes in Black and White Women with Early-Stage Breast Cancer.
|
|
Academic Article
|
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.
|
|
Academic Article
|
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
|
|
Academic Article
|
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients.
|
|
Academic Article
|
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer.
|
|
Academic Article
|
Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer.
|
|
Academic Article
|
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence.
|
|
Academic Article
|
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.
|
|
Academic Article
|
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
|
|
Academic Article
|
Demographic and Clinical Characteristics Associated With Familiarity, Interest, and Use of Integrative Therapies Among Patients With Breast Cancer.
|
|
Academic Article
|
Stress, Isolation, and Sleep Quality among Breast Cancer Survivors throughout the COVID-19 Pandemic: A Longitudinal Study in a Multi-Ethnic Cohort.
|
|
Academic Article
|
Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer.
|
|
Academic Article
|
Racial/Ethnic Disparities in Telemedicine Utilization and Satisfaction Among Breast Cancer Patients During the COVID-19 Pandemic: A Mixed-Methods Analysis.
|
|
Academic Article
|
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
|
|
Academic Article
|
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
|
|
Academic Article
|
Validation of the RSClin risk calculator in the National Cancer Data Base.
|
|
Academic Article
|
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
|
|
Academic Article
|
Racial differences in familiarity, interest, and use of integrative medicine among patients with breast cancer.
|
|
Academic Article
|
Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer.
|
|
Academic Article
|
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
|
|
Academic Article
|
The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
|
|
Academic Article
|
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
|
|
Academic Article
|
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
|
|
Academic Article
|
Racial differences in familiarity, interest, and use of integrative medicine among patients with breast cancer.
|
|
Academic Article
|
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
|
|
Academic Article
|
Assessing the Relationship Between Neighborhood Socioeconomic Disadvantage and Telemedicine Use Among Patients With Breast Cancer and Examining Differential Provisions of Oncology Services Between Telehealth and In-Person Visits: Quantitative Study.
|